Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

Selective RET kinase inhibition for patients with RET-altered cancers

(2018) V Subbiah et al.   ANNALS OF ONCOLOGY

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

(2018) Takeshi Hirota et al.   CLINICAL PHARMACOKINETICS

ALK inhibitors, resistance development, clinical trials

(2018) J.M. Rothenstein et al.   Current Oncology

Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation

(2018) Garry Ceccon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

(2018) Xin Hong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing

(2018) Rahul Nahar et al.   Nature Communications

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

(2018) Vivek Subbiah et al.   Cancer Discovery

Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.

(2018) Yan Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug

(2018) Amit Sharma et al.   Chem

Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy

(2018) Ankur Sharma et al.   Nature Communications

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors

(2017) Assunta Sgambato et al.   Expert Review of Anticancer Therapy

Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer

(2017) Hiroki Osumi et al.   Gastric Cancer

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

(2017) Xian Chan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases

(2017) Xiaoliang Wu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial

(2017) D.R. Camidge et al.   Journal of Thoracic Oncology

MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy

(2017) Daniel Morgensztern et al.   Journal of Thoracic Oncology

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

(2017) Hironori Uruga et al.   Journal of Thoracic Oncology

Plasma ctDNA Analysis for Detection of the EGFR  T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

(2017) Suzanne Jenkins et al.   Journal of Thoracic Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

EGFR T790M mutation testing within the osimertinib AURA Phase I study

(2017) Simon Dearden et al.   LUNG CANCER

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

(2017) Kazuhiko Shien et al.   MOLECULAR CANCER THERAPEUTICS

Tracking the Evolution of Non–Small-Cell Lung Cancer

(2017) Mariam Jamal-Hanjani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin

(2017) Yong Hu et al.   OncoTargets and Therapy

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

(2017) Sean Caenepeel et al.   Oncotarget

Single-cell protein-mRNA correlation analysis enabled by multiplexed dual-analyte co-detection

(2017) Haibiao Gong et al.   Scientific Reports

Crizotinib targets in glioblastoma stem cells

(2017) Audelaure Junca et al.   Cancer Medicine

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

(2017) Kiyotaka Yoh et al.   Lancet Respiratory Medicine

Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC.

(2017) Ulrich Robert Mansmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients

(2017) Florence Koeppel et al.   PLoS One

What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)

(2016) A. Drilon et al.   ANNALS OF ONCOLOGY

Simple Method To Prepare Oligonucleotide-Conjugated Antibodies and Its Application in Multiplex Protein Detection in Single Cells

(2016) Haibiao Gong et al.   BIOCONJUGATE CHEMISTRY

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

(2016) Alexander Drilon et al.   CANCER RESEARCH

Metabolic Heterogeneity in Human Lung Tumors

(2016) Christopher T. Hensley et al.   CELL

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

(2016) C. Karlovich et al.   CLINICAL CANCER RESEARCH

ROS1 Kinase Inhibitors for Molecular-Targeted Therapies

(2016) M.M. Al-Sanea et al.   CURRENT MEDICINAL CHEMISTRY

The potential of liquid biopsies

(2016) Anna Buder et al.   CURRENT OPINION IN ONCOLOGY

Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer

(2016) Le-Le Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

(2016) S. Ramalingam et al.   Journal of Thoracic Oncology

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

(2016) Glenwood Goss et al.   LANCET ONCOLOGY

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

(2016) Yong Jia et al.   NATURE

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

(2016) Trever G Bivona et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Single-cell multimodal profiling reveals cellular epigenetic heterogeneity

(2016) Lih Feng Cheow et al.   NATURE METHODS

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

(2016) Akihito Tsuji et al.   Targeted Oncology

Genomic heterogeneity of multiple synchronous lung cancer

(2016) Yu Liu et al.   Nature Communications

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

(2016) Praveena S. Thiagarajan et al.   Oncotarget

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

(2016) Sun Min Lim et al.   Oncotarget

Spatial Heterogeneity in the Tumor Microenvironment

(2016) Yinyin Yuan   Cold Spring Harbor Perspectives in Medicine

KRASin Non–Small-Cell Lung Cancer

(2016) Stéphane Renaud et al.   JAMA Oncology

Molecular Testing for Targeted Therapy in Advanced Non–Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration

(2015) Chiara Casadio et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

(2015) C. Cremolini et al.   ANNALS OF ONCOLOGY

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

(2015) M. J. Niederst et al.   CLINICAL CANCER RESEARCH

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

(2015) S. Napolitano et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

(2015) C. G. Hoffman-Luca et al.   CLINICAL CANCER RESEARCH

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

(2015) Volker Heinemann et al.   EUROPEAN JOURNAL OF CANCER

Therapeutic management of ALK+nonsmall cell lung cancer patients

(2015) Boris Duchemann et al.   EUROPEAN RESPIRATORY JOURNAL

Stromal biology and therapy in pancreatic cancer: a changing paradigm

(2015) Albrecht Neesse et al.   GUT

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer

(2015) Shigehira Saji et al.   International Journal of Clinical Oncology

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib forEGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2015) Melissa L. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

(2015) Antonio Marchetti et al.   Journal of Thoracic Oncology

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

(2015) Matthew G Oser et al.   LANCET ONCOLOGY

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor

(2015) Adriana Estrada-Bernal et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

(2015) Devon A. Lawson et al.   NATURE

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Targeting mitochondria metabolism for cancer therapy

(2015) Samuel E Weinberg et al.   Nature Chemical Biology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker

(2015) P. C. Ma   Cancer Discovery

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

(2015) L. G. Ahronian et al.   Cancer Discovery

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells

(2015) Kyu-Tae Kim et al.   GENOME BIOLOGY

The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas

(2015) Hongxiang Wang et al.   NEOPLASIA

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer

(2015) Monika Joshi et al.   PLoS One

Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells

(2015) Roya Navab et al.   NEOPLASIA

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

(2014) Marco Gerlinger et al.   NATURE GENETICS

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

(2013) G. Etienne et al.   HAEMATOLOGICA

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2013) Hubert Piessevaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

(2013) Ali Bashashati et al.   JOURNAL OF PATHOLOGY

Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation

(2013) Hyeong Ryul Kim et al.   Molecular Oncology

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

(2012) W. Wang et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

(2012) Sai-Hong Ignatius Ou et al.   ONCOLOGIST

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction

(2011) S. Benvenuti et al.   CANCER RESEARCH

MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents

(2011) W. Fan et al.   CANCER RESEARCH

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

(2010) Elisa Benedettini et al.   AMERICAN JOURNAL OF PATHOLOGY

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Drugging Drug Resistance

(2010) Jan-Hermen Dannenberg et al.   CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

(2009) T. Yamada et al.   CLINICAL CANCER RESEARCH

Shifting paradigms: the seeds of oncogene addiction

(2009) Charles L Sawyers   NATURE MEDICINE

Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer

(2009) Adi F. Gazdar   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

(2008) F. L. Chen et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

(2008) A. Tatematsu et al.   CLINICAL CANCER RESEARCH

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA